Company Monitoring Page for Eli-Lilly

latest headlines for company on cafepharma

Sun, 01/27/19 - 07:07 pm
Tags:
earnings, drug pricing, Genentech, Eli Lilly, Medtronic, Roche, M&A, Takeda, GSK, FDA
CVS to cover migraine drugs from Teva, Lilly; excludes Amgen
Reuters
Sat, 01/26/19 - 11:56 am
Tags:
CVS Health, migraines, Amgen, Teva Pharmaceutical, Eli Lilly, Aimovig, Ajovy, Emgality
In another setback for Eli Lilly, FDA follows EMA in calling for a halt to new Lartruvo prescriptions
Endpoints
Fri, 01/25/19 - 12:12 pm
Tags:
Eli Lilly, cancer, Lartruvo, FDA, EMA
A flashy 2019 start to pharma M&A, but will it last?
Biopharma Dive
Tue, 01/22/19 - 11:55 pm
Tags:
M&A, Celgene, Bristol-Myers Squibb, Eli Lilly, Loxo Oncology
Lilly’s second immune-oncology candidate using Zymeworks’ Azymetric platform to start clinical trials
Pharmaceutical Business Review
Mon, 01/21/19 - 10:49 am
Tags:
Eli Lilly, Zymeworks, drug development, Azymetric platform
On heels of Loxo buy, Lartruvo setback deals a blow to Lilly's oncology hopes
Fierce Pharma
Fri, 01/18/19 - 11:30 am
Tags:
Eli Lilly, Lartruvo, soft tissue sarcoma, clinical trials
No bidding war for Loxo, so did Lilly overpay? Don’t rush to judgment, analysts say
Fierce Pharma
Fri, 01/18/19 - 10:27 am
Tags:
Eli Lilly, Loxo Oncology, M&A
Lilly price break reverses NICE’s 'No' ruling on breast cancer drug Verzenio
Fierce Pharma
Fri, 01/18/19 - 12:09 am
Tags:
Eli Lilly, NICE, Verzenio, breast cancer
Looking to make a splash at JPMorgan, Eli Lilly rushed to put its $8B buyout deal together for Loxo in 10 days
Endpoints
Thu, 01/17/19 - 11:10 am
Tags:
Eli Lilly, Loxo Oncology, M&A, JPMHC 2019
Can Botox hang with CGRP in migraine? Allergan says yes; analysts are skeptical
Fierce Pharma
Mon, 01/14/19 - 11:11 am
Tags:
Allergan, Botox, migraines, CGRP blockers, Amgen, Novartis, Aimovig, Teva Pharmaceutical, Ajovy, Eli Lilly, Emgality
NASH Space in Focus in 2019 as Firms Look to Diversify
Yahoo/Zacks.com
Sun, 01/13/19 - 11:32 am
Tags:
NASH, Gilead Sciences, Merck, Roche, Novartis, Jecure Therapeutics, Pfizer, Celgene, Eli Lilly
Lilly eyes more cancer deals, but wary of CAR-T, gene therapy
Yahoo/Reuters
Sat, 01/12/19 - 08:49 pm
Tags:
Eli Lilly, Loxo Oncology, M&A, CAR-T, gene therapy
JPM recap: Must-reads of the week, from FDA to IPO to M&A and more
Fierce Pharma
Fri, 01/11/19 - 10:25 am
Tags:
JPMHC 2019, Merck, FDA, M&A, Celgene, Bristol-Myers Squibb, Genevant, IPOs, Eli Lilly, Novartis, GSK, Teva Pharmaceutical, Alexion, Pear Therapeutics
JP Morgan's Dimon hosted a private dinner for pharma executives, and a major topic was Amazon
CNBC
Thu, 01/10/19 - 09:50 am
Tags:
JNJ, Pfizer, Eli Lilly, Jamie Dimon, Amazon, JPMHC 2019
Does Eli Lilly's $8 Billion Splurge Make Array BioPharma a Buy Now?
Motley Fool
Wed, 01/9/19 - 09:43 am
Tags:
Eli Lilly, Loxo Oncology, Array Biopharma, M&A
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
BioSpace
Wed, 01/9/19 - 09:40 am
Tags:
JPMHC 2019, M&A, Eli Lilly, Loxo Oncology, SAGE Therapeutics, Sanofi, Regeneron, Bristol-Myers Squibb, Celgene, Novartis, Gilead Sciences
Don't fret about Lilly's 3rd-to-market start in CGRP, exec says. It's got big plans in migraine and pain, too
Fierce Pharma
Wed, 01/9/19 - 09:38 am
Tags:
Eli Lilly, Emgality, migraines, CGRP blockers
Is Eli Lilly Overpaying for Loxo Oncology?
Motley Fool
Tue, 01/8/19 - 09:30 am
Tags:
Eli Lilly, Loxo Oncology, M&A, Vitrakvi
Eli Lilly to buy Loxo Oncology for $8 billion in huge bet on cancer genetics
Stat
Mon, 01/7/19 - 10:09 am
Tags:
Eli Lilly, Loxo Oncology, M&A
Does Pfizer Have A Multibillion-Dollar Replacement For Opioids?
Investors Business Daily
Mon, 12/31/18 - 12:15 pm
Tags:
Pfizer, Eli Lilly, tanezumab, painkillers, opioids

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.